Registration Closed: Strategic Investment and Alliances
Thu, May 8 8:00 am – 10:00 am
We are sorry, but registration for this event is now closed. We appreciate your support and hope to see you at future events!
TO REGISTER
Email your name, title and company to register@massbio.org. Please include "5/8 Finance" in the subject line.
This event is free of charge and open to MBC Member companies and their employees only.
For more information on Membership, contact Lori Gold at lori.gold@massbio.org or 617-674-5149
Registration closes at approximately 3pm one day prior to a scheduled meeting. Unless a meeting is closed due to capacity you may attend as a walk-in registrant.
This meeting will be held at the MBC Offices, located on the ninth floor of One Cambridge Center, Cambridge, MA 02142.
Large pharmaceutical and biotech companies are increasing their investments in innovative companies, and these partnerships are often key to building a successful company.
A strategic investment or alliance can increase the valuation of your company, offer market validation, and also offer critical support in the form of resources, technology, and operations.
Join us on May 8th as we bring together a distinguished group of panelists to determine the types of deals available to smaller companies, how to secure an alliance or investment, and most importantly, how to manage the relationship.
Topics that will be explored include:
How to identify the best partner for your company
The types of partnerships offered by larger companies, and how to determine if your company is a candidate for an investment, license, or an M&A
The best strategies for securing a strategic investment or alliance
How strategic investment differs from VC investment
The importance of deal structure and key contract terms
The pros and cons of an investment or alliance with a larger company
The do's and don'ts in prospecting for the deal, negotiating the deal, and managing the relationship
Moderator
Marc Recht , Partner, Cooley Godward Kronish LLP
Panelists
Gary Lubin, Co-Founder, Merck Capital Ventures
http://www.merckcapitalventures.com
Dr. Markus Goebel, Managing Director, Novartis Venture Fund
http://www.venturefund.novartis.com
Catherine Oyler, Evaluation Director, Strategic Planning & Business Development, AstraZeneca
http://www.astrazeneca.com/article/11223.aspx
Rainer Fuchs, PhD, Vice President and Executive Director of bi3 (Biogen incubator), Biogen Idec
http://www.biogenidec.com/bi3
Myles Clouston, Associate, Equity Investment Research, Johnson & Johnson Development Corporation
http://www.jjdevcorp.com
Christine Foster, Ph.D., Assistant Vice-President, Global Business Development, Wyeth Pharmaceuticals
http://www.wyeth.com/gbd
PHONE: 617.674.5100
EMAIL: